Literature DB >> 35529084

Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease.

Toshifumi Nakamura1, Sophie Girerd2,3, Frederic Jaisser1,3, Jonatan Barrera-Chimal4,5.   

Abstract

Chronic kidney disease is a major global health challenge, and mineralocorticoid receptor (MR) signaling is thought to play a role in disease progression. The classic role of the MR is the regulation of fluid and electrolyte homeostasis via differential gene expression, and recently its role in modulating inflammation and fibrosis has been identified. In addition to expression of the MR in renal epithelial cells, it is also found in nonepithelial cells, such as endothelial cells, vascular smooth muscle cells, podocytes, and fibroblasts. Targeting the MR in these cells may play a role in offering protection against inflammation and fibrosis in the kidneys and the cardiovascular system. Herein, data from preclinical cell-specific MR knockout mouse models and in vitro studies that help uncover the role of the MR in nonepithelial cells are presented. This review also discusses several potential targets that offer opportunities for the targeting of MR signaling in nonepithelial cells.
© 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic kidney disease; mineralocorticoid receptor; nonepithelial cells

Year:  2022        PMID: 35529084      PMCID: PMC9073223          DOI: 10.1016/j.kisu.2021.11.004

Source DB:  PubMed          Journal:  Kidney Int Suppl (2011)        ISSN: 2157-1716


  66 in total

1.  c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats.

Authors:  Glaucia E Callera; Augusto C I Montezano; Alvaro Yogi; Rita C Tostes; Ying He; Ernesto L Schiffrin; Rhian M Touyz
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

Review 2.  Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease.

Authors:  Akira Nishiyama
Journal:  Hypertens Res       Date:  2018-12-06       Impact factor: 3.872

Review 3.  30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor null mice: informing cell-type-specific roles.

Authors:  Timothy J Cole; Morag J Young
Journal:  J Endocrinol       Date:  2017-05-26       Impact factor: 4.286

Review 4.  Ménage à trois: aldosterone, sodium and nitric oxide in vascular endothelium.

Authors:  Johannes Fels; Hans Oberleithner; Kristina Kusche-Vihrog
Journal:  Biochim Biophys Acta       Date:  2010-03-17

5.  Mineralocorticoid receptor activation promotes vascular cell calcification.

Authors:  Iris Z Jaffe; Yin Tintut; Brenna G Newfell; Linda L Demer; Michael E Mendelsohn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-01-18       Impact factor: 8.311

Review 6.  Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.

Authors:  Peter Rossing
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

7.  The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling.

Authors:  Jonatan Barrera-Chimal; Gabriel R Estrela; Sebastian M Lechner; Sébastien Giraud; Soumaya El Moghrabi; Shiem Kaaki; Peter Kolkhof; Thierry Hauet; Frédéric Jaisser
Journal:  Kidney Int       Date:  2018-03-13       Impact factor: 10.612

8.  Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease.

Authors:  Shigeru Shibata; Miki Nagase; Shigetaka Yoshida; Wakako Kawarazaki; Hidetake Kurihara; Hirotoshi Tanaka; Jun Miyoshi; Yoshimi Takai; Toshiro Fujita
Journal:  Nat Med       Date:  2008-11-23       Impact factor: 53.440

9.  Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation.

Authors:  Jonatan Barrera-Chimal; Leslie Rocha; Isabel Amador-Martínez; Rosalba Pérez-Villalva; Rafael González; Cesar Cortés-González; Norma Uribe; Victoria Ramírez; Nathan Berman; Gerardo Gamba; Norma A Bobadilla
Journal:  Nephrol Dial Transplant       Date:  2019-05-01       Impact factor: 5.992

10.  RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.

Authors:  Sandor Koszegi; Agnes Molnar; Lilla Lenart; Judit Hodrea; Dora Bianka Balogh; Tamas Lakat; Edgar Szkibinszkij; Adam Hosszu; Nadja Sparding; Federica Genovese; Laszlo Wagner; Adam Vannay; Attila J Szabo; Andrea Fekete
Journal:  J Physiol       Date:  2018-11-02       Impact factor: 5.182

View more
  3 in total

Review 1.  The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis.

Authors:  James M Luther; Agnes B Fogo
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

Review 2.  Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.

Authors:  Peter Rossing
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

Review 3.  The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets.

Authors:  Morley D Hollenberg; Murray Epstein
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.